Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter.
Palvella Therapeutics Stock Down 2.2 %
PVLA opened at $27.27 on Wednesday. The firm has a fifty day moving average price of $19.36. The stock has a market capitalization of $306.00 million, a PE ratio of -2.25 and a beta of 0.54. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $29.27.
Analyst Ratings Changes
Several equities analysts recently weighed in on the company. Jones Trading assumed coverage on Palvella Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $45.00 price target for the company. Cantor Fitzgerald began coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $39.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. TD Cowen began coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Scotiabank started coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $43.20.
About Palvella Therapeutics
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Featured Stories
- Five stocks we like better than Palvella Therapeutics
- What is Short Interest? How to Use It
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- EV Stocks and How to Profit from Them
- NVIDIA Insiders Sell: This Is What It Means for the Market
- How to Most Effectively Use the MarketBeat Earnings Screener
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
